Pancreatic Ductal Adenocarcinoma Clinical Trials
Pancreatic Ductal Adenocarcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for pancreatic Ductal Adenocarcinoma. Corterve aggregates actively recruiting Pancreatic Ductal Adenocarcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Pancreatic Ductal Adenocarcinoma studies
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaNCT07490301PHASE2, PHASE3AbbVieZion, Illinois
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsNCT04657068PHASE1, PHASE2Artios Pharma LtdBirmingham, Alabama
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsNCT06445062PHASE1, PHASE2Revolution Medicines, Inc.Chandler, Arizona
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941PHASE2AstraZenecaOrange, California
- Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDACNCT07733674PHASE1Radiomedix, Inc.Houston, Texas
- PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal AdenocarcinomaNCT07047807NAMassachusetts General HospitalBoston, Massachusetts
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsNCT06218914PHASE1AstraZenecaDuarte, California
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152PHASE3Immuneering CorporationPhoenix, Arizona
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerNCT07644559PHASE2Verastem, Inc.Los Angeles, California
- EUS-RFA PANCARDINAL-1 TrialNCT04990609PHASE2The University of Texas Health Science Center, HoustonHouston, Texas
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232PHASE3Revolution Medicines, Inc.Phoenix, Arizona
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersNCT06562192PHASE1Novartis PharmaceuticalsBirmingham, Alabama
See all 101 recruiting Pancreatic Ductal Adenocarcinoma trials →
Pancreatic Ductal Adenocarcinoma trials by state
Pancreatic Ductal Adenocarcinoma trials by metro
Frequently asked questions
- How do I find recruiting Pancreatic Ductal Adenocarcinoma clinical trials?
- Corterve aggregates actively recruiting Pancreatic Ductal Adenocarcinoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Pancreatic Ductal Adenocarcinoma clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Pancreatic Ductal Adenocarcinoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.